Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554673 | 0.93 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL23967333 | 0.91 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL12788260 | 0.91 | CYP2C9 (0.51) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL16596142 | 0.89 | CYP2C9 (0.49) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL18473669 | 0.87 | CYP2C9 (0.61) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL3846150 | 0.86 | CYP2C9 (0.74) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL8530617 | 0.85 | CYP2C9 (0.59) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL1763295 | 0.85 | CYP2C9 (0.72) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6441064 | 0.85 | CYP2C9 (0.64) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL23387038 | 0.85 | CYP2C9 (0.57) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299382-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | EP | claimed |
| US-6573262-B2 | Compounds for treating mammals infected with HIV virus | BRISTOL-MYERS SQIBB COMPANY | 2003-06-03 | — | — | US | claimed |
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-04-10 | — | — | US | claimed |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2016-03-24 | — | — | US | disclosed |
| US-9181224-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | IDO1, IDO2, ITPA | CYP2C9 2370/4885CYP3A4 469/4885CYP2D6 831/4885 |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2BP2 | CYP2C9 4672/4885CYP3A4 3518/4885CYP2D6 2910/4885 |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | CYP2C9 4639/4885CYP3A4 3336/4885CYP2D6 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.